Deutsche Bank Starts IMS Health Holdings (IMS) at Buy

Deutsche Bank initiated coverage on IMS Health Holdings (NYSE: IMS) with a Buy rating and a price target of $28.00.

Analyst Paul Ginocchio said, "IMS Health is in the early stages of the move from a $5bn up to a $75bn addressable market, allowing IMS to touch all major areas of pharmaceutical company spend from just sales & marketing previously. With its 60+ year legacy as the leading provider of pharmaceutical data in 100 countries, combined with now broader market opportunities due to new capabilities, IMS is well positioned to achieve mid-single digit organic rev growth and strong FCF generation. We rate IMS a Buy as it trades at a discount to peers on PE and unlevered FCF."

For an analyst ratings summary and ratings history on IMS Health Holdings click here. For more ratings news on IMS Health Holdings click here.

Shares of IMS Health Holdings closed at $25.21 yesterday.

You May Also Be Interested In

• DA Davidson Starts Everus (ECG) at Buy
• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Cummins (CMI) PT Lowered to $675 at Jefferies